Industry news

Swag, shindigs lure all to exhibit hall, but dealmaking was goal

Marie Powers / BioWorld

Although the sprawling exhibit hall at the BIO International Convention sometimes seems like an indoor advertising showcase for big pharma, it also serves as an essential meeting point for smaller companies seeking to expand their networks or attract that critical initial partner. Pity the poor exhibitor stuck in a back corner who has to compete with floor to ceiling exhibits featuring gourmet delicacies, live entertainment, celebrities and visiting dignitaries.

Moscow researchers use magnetite nanoparticles to develop cancer drugs

MarchMont Innovation News

Scientists at MISiS, a leading Russian technology university in Moscow, are developing a new family of theranostic (a portmanteau of the words “therapy” and “diagnostic”) magnetite nanoparticles based materials that are considered unique in Russia and abroad and expected to enable the development of high-efficacy cancer drugs, portal Rusnanonet.ru  reported , citing a source in the Moscow-based university. 

Russian biotech company launches exports into U.S.

MarchMont Innovation News

Semiotic, a Russian biotech developer, will have at least five years for the distribution of its proprietary solution in the U.S. via its partner GlycoTech Corporation, a sizable supplier of reagents for glycobiological research in the United States. The product the partners will be marketing under their recent agreement is a carbohydrate microchip, or glycochip, enabling medical researchers to determine the quantity of glycan-binding proteins in a biosample under study.

Pharma can power intra-BRICS trade

Elena Krovvidi / Russia & India Report

Coralmed pharmaceutical company plans to expand its operations and drive growth within Russia by local repackaging of its products, followed by complete technology transfer to local manufacturers, said BP Singh, General Director of the company, in an interview to RIR.

Top 10 med tech R&D budgets in 2014

Stacy Lawrence / Fierce Medical Devices

The largest med tech companies wield a huge amount of cash to funnel into R&D. The top 10 largest R&D spenders in med tech* spent a whopping $10.78 billion on developing new medical devices and diagnostics last year. That's a decline of 2%.

Report: Novo, Sanofi and Merck dominate global diabetes market

Emily Wasserman / FiercePharma

It's a good time to be a diabetes drugmaker. The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year.

What's worrying pharma? Reimbursement, yes, but also M&A, global threats, and the economy

Tracy Staton / Fierce Pharma

If you've spent any time reading biopharma's securities filings, you've noticed the litany of potential problems every company discloses--everything from natural disasters and terrorist attacks to patent lawsuits and regulatory setbacks.

Russian amendments to test Indian Pharma

Alexandra Katz / Russia & India Report

Russia-India pharmaceutical cooperation traditionally receives a lot of attention at the highest levels. However, in crisis conditions, companies have had to develop their own survival strategies in which competitiveness and innovation take first place. Some amendments in Russia will test the Indian pharmaceutical sector.

MIT to launch nonprofit focused on empirical evaluation of digital health products

MIT's Hacking Medicine program, which studies digital health and medicine, is set to become a nonprofit institute devoted to empirically evaluating the real-world effectiveness of the latest medical gadgets, gizmos, smartphone apps and the like.

Foundation Medicine, IMS Health Collaborate on Precision Oncology

GenomeWeb

Information and technology services company IMS Health will combine its Real-World Evidence platform with Foundation Medicine's FoundationCore knowledgebase, enabling clients to interpret real-world oncology outcomes, the firms said today.